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e v i d e n c e - b a s e d  a n s w e r
low-dose	 inhaled	 corticosteroids	 are	 the	
preferred	 treatment	 for	 children	 with	 mild	
persistent	 asthma	 because	 they	 demon-
strate	superior	reduction	in	severity	and	fre-
quency	of	asthma	exacerbations	compared	
with	 alternatives	 (strength	 of	 recommenda-
tion	[sor]:	A,	based	on	multiple	randomized	
controlled	trials).	as	add-on	therapy,	nedo-
cromil,	theophylline,	and	cromolyn	have	all	
demonstrated	a	modest	benefit	in	symptom	
control;	 leukotriene	 receptor	 antagonists	
are	also	recommended	based	on	data	from	
older	children	(sor:	B,	cohort	study).	unlike	
treatment	 of	 moderate	 or	 severe	 asthma,	
long-acting	 beta-agonists	 are	 not	 recom-
mended	(sor:	A,	randomized	trials).
c l i n i c a l  c o m m e n t a r y
Clear medication choices for mild 
asthma are supported by good evidence 
Physicians	 who	 routinely	 treat	 children	
with	asthma	are	fortunate	to	have	the	body	
of	 evidence	 outlined	 in	 this	 review.	 Clear	
medication	choices	are	supported	in	most	
instances	 by	 relatively	 clear	 comparisons	
with	 alternatives.	 In	 my	 practice,	 where	
many	children	can	be	classified	in	the	“mild	
persistent”	category,	I	am	always	surprised	
at	how	many	patients’	families	lack	a	clear	
understanding	of	the	factors	that	trigger	a	
child’s	asthma	and	how	to	avoid	them.	
another	 common	 clinical	 scenario	
among	 children	 and	 adolescents	 is	 exer-
cise-induced	 asthma.	 Depending	 on	 the	
sport,	 the	 asthma	 can	 be	 classified	 as	
“mild	persistent”	or	“mild	intermittent.”	for	
true	intermittent	symptoms,	my	clinical	ex-
perience	 (and	 often	 parental	 preference)	
argues	for	pre-activity	treatment	with	short	
acting	beta-agonists	as	the	most	practical	
therapy.
John Heintzman, MD
oregon	Health	and	science	university,	
Portland
n Evidence summary
Mild persistent asthma is defined as 
forced expiratory volume over 1 second 
(FEV1) ≥80% predicted, with daytime 
symptoms more than twice per week 
but less than once daily, and night-
time symptoms more often than twice 
monthly.1 
Low-dose inhaled corticosteroids
Two large randomized trials support us-
ing low-dose inhaled corticosteroids in 
these children. The Childhood Asthma 
Management Program (CAMP) study, 
which included 1041 children, evalu-
ated treatment with either budesonide 
or nedocromil vs placebo. Patients 
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taking budesonide had a lower rate of 
urgent care visits (absolute risk reduc-
tion [ARR]=10%; number needed to 
treat [NNT]=10; P=.02) compared with 
children taking nedocromil (ARR=6%; 
NNT=17; P=.02). The urgent care visits 
were reported as number of visits per 100 
person-years. 
In practical terms, this means that in 
order to decrease 1 urgent care visit, 1 
patient would need to take budesonide 
for 10 years. However, because rates are 
not necessarily homogenous over time, 
the number of visits decreased during the 
first year may be different than the num-
ber of events decreased throughout the 
tenth year. 
Children taking budesonide experi-
enced 21.5% more episode-free days than 
those taking placebo (P=.01). No change 
was observed in the nedocromil group.2 In 
the inhaled Steroid Treatment As Regular 
Therapy (START) in early asthma study, 
budesonide demonstrated a 44% relative 
reduction in time to first severe asthma 
related event, compared with placebo 
(95% confidence interval [CI], 0.45–0.71; 
NNT=44; P=.0001).3 
Theophylline
Theophylline is considered an alterna-
tive to inhaled corticosteroids. One 
study compared beclomethasone with 
theophylline in 195 children. This study 
found near-equivalent efficacy in doc-
tor visits, hospitalizations, monthly peak 
expiratory flow rates, and FEV1; however, 
beclomethasone was superior to theoph-
ylline in maintaining symptom control 
and decreasing the use of inhaled bron-
chodilators and systemic steroids. 
When compared with beclometha-
sone, theophylline was linked to 14% 
more central nervous system adverse ef-
fects (P<.001) and 17% more gastro- 
intestinal disturbances (P<.001). Although 
beclomethasone induced more oral candi-
diasis compared with theophylline (8.9% 
vs 2.4%; P<.001), the incidence of this in-
fection can be reduced by using a spacer. 
Long-term systemic effects
The potential long-term adverse system-
ic effects of inhaled corticosteroids on 
growth, bone metabolism, and pituitary-
adrenal function call for longer-term 
studies.4 A systematic review of 15 trials 
reported that the protective effect of leu-
kotriene receptor antagonists is inferior 
to inhaled corticosteroids for adults (rela-
tive risk [RR]=1.71; 95% CI, 1.40–2.09); 
however, evidence is insufficient to ex-
trapolate this to children.5	
Beta-agonists
Evidence does not support use of long-
acting beta-agonists as monotherapy or 
in combination with other medications 
for children with mild persistent asthma. 
Although 1 study showed an improve-
ment in lung function for children taking 
budesonide plus formoterol compared 
with budesonide alone, the rate of severe 
exacerbations was lower for those tak-
ing budesonide alone (62% decrease vs 
55.8% decrease; P=.001). Both groups 
had a 32% decrease in the number of res-
cue inhalations per day when compared 
with placebo (P=.0008).6
Recommendations from others 
Recommendations are listed in the 
TaBLE.1,7,8 Unlike the NAEPP and GINA 
asthma guidelines, the BTS/SIGN asthma 
guidelines define no objective measure-
ment or staging classification to diagnose 
asthma among children. Diagnosis is de-
termined by a child’s response to medica-
tion.8 Independent of any daily controller 
medication use, all children should have 
a short acting bronchodilator on hand in 
case of an acute attack.1,8,9 
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Recommendations for treating mild persistent asthma
GuiDeline DAily ConTroller MeDiCATion AlTernATive TreATMenT
national asthma Education		 low-dose	inhaled	corticosteroids	 Children	<5:	cromolyn,	lTras	
and Prevention Program 	 	 Children	>5:	cromolyn,	lTras,	nedocromil,		
(NaePP)1	 	 sustained	release	theophylline
Global initiative for		 low-dose	inhaled	corticosteroids	 all	children:	sustained	released	theophylline,		
asthma	(GINa)7	 	 Cromone,	lTras
British Thoracic Society/	 Inhaled	steroids	 all	children:	lTras,	theophylline	
Scottish intercollegiate 	 	 Children	>5:	cromones,	nedocromil	
Guidelines network		
(bTs/sIGN)8	
lrTa,	leukotriene	receptor	antagonists.
Sources:	NaePP,	J Allergy Clin Immunol 20021;	GINa,	Guidelines and Resources	2005,7	and	bTs/sIGN,	Thorax	2003.8
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